{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T03:56:50Z","timestamp":1769745410992,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.clgc.2016.09.006","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T00:45:09Z","timestamp":1476924309000},"page":"e345-e355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma\u2014Results From a Tertiary Cancer Center in India"],"prefix":"10.1016","volume":"15","author":[{"given":"Anant","family":"Ramaswamy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanita","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay M.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rushabh","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram Abhinav","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilesh","family":"Sable","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Palak","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar","family":"Prabhash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.09.006_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2016.09.006_bib2","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.09.006_bib3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clgc.2016.03.001","article-title":"The evolution of nephrectomy and patient characteristics in metastatic renal cell carcinoma patients enrolled into first-line tyrosine kinase inhibitors clinical trials","volume":"14","author":"Sella","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2016.09.006_bib4","first-page":"e141","article-title":"Economic burden of oral tyrosine kinase inhibitors among privately insured patients diagnosed with metastatic renal cell carcinoma","volume":"7","year":"2015","journal-title":"Am J Pharm Benefits"},{"key":"10.1016\/j.clgc.2016.09.006_bib5","first-page":"11","article-title":"Concurrent chemoradiation for cancer of the cervix: results of a multi-institutional study from the setting of a developing country (India)","volume":"1","author":"Nandakumar","year":"2015","journal-title":"J\u00a0Glob Oncol"},{"issue":"suppl 3","key":"10.1016\/j.clgc.2016.09.006_bib6","doi-asserted-by":"crossref","first-page":"iii49","DOI":"10.1093\/annonc\/mdu259","article-title":"Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Escudier","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.09.006_bib7","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.09.006_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"1990","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.09.006_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/annonc\/mdv504","article-title":"Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD Registry","volume":"27","author":"Wagstaff","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.09.006_bib10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ejca.2013.10.010","article-title":"Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2","volume":"50","author":"Soerensen","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.09.006_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clgc.2012.01.007","article-title":"Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients","volume":"10","author":"Shek","year":"2012","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2016.09.006_bib12","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/annonc\/mdq651","article-title":"Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings","volume":"22","author":"Beck","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.09.006_bib13","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/cncr.24864","article-title":"Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America","volume":"116","author":"Stadler","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.09.006_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/bjc.2015.196","article-title":"Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma","volume":"113","author":"Gore","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2016.09.006_bib15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4103\/0019-509X.180851","article-title":"Clinical characteristics of renal cell carcinoma: five years' review from a tertiary hospital in Eastern India","volume":"53","author":"Ray","year":"2016","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.clgc.2016.09.006_bib16","first-page":"624","article-title":"Renal cell carcinoma in India demonstrates early age of onset and a late stage of presentation","volume":"140","author":"Agnihotri","year":"2014","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.clgc.2016.09.006_bib17","doi-asserted-by":"crossref","first-page":"806","DOI":"10.4103\/2230-8210.117212","article-title":"Emerging risk factors for cardiovascular diseases: Indian context","volume":"17","author":"Gupta","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.clgc.2016.09.006_bib18","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.09.006_bib19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00432-012-1148-8","article-title":"Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features","volume":"138","author":"Lee","year":"2012","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clgc.2016.09.006_bib20","doi-asserted-by":"crossref","first-page":"e0120877","DOI":"10.1371\/journal.pone.0120877","article-title":"A\u00a0systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting","volume":"10","author":"Fishman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2016.09.006_bib21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4103\/0019-509X.118725","article-title":"Sunitinib in metastatic renal cell carcinoma: a single-center experience","volume":"50","author":"Krishna","year":"2013","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.clgc.2016.09.006_bib22","doi-asserted-by":"crossref","first-page":"20089","DOI":"10.1038\/srep20089","article-title":"The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma","volume":"6","author":"Qin","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clgc.2016.09.006_bib23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdt492","article-title":"Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials","volume":"25","author":"Heng","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.09.006_bib24","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","article-title":"Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.09.006_bib25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 4","key":"10.1016\/j.clgc.2016.09.006_bib26","article-title":"Sunitinib versus sorafenib as first-line therapy for patients with metastatic renal cell carcinoma with favorable or intermediate MSKCC risk factors: a multicenter randomized trial, CROSS-J-RCC","volume":"32","author":"Tomito","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.09.006_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.09.006_bib28","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/bjc.2013.119","article-title":"Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008)","volume":"108","author":"Wahlgren","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2016.09.006_bib29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","article-title":"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study","volume":"16","author":"Ko","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2016.09.006_bib30","unstructured":"India GDP per capita 1960-2016. Available at: http:\/\/www.tradingeconomics.com\/india\/gdp-per-capita. Accessed: July 26,\u00a02016."}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316302816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767316302816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:27:38Z","timestamp":1761564458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767316302816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1558767316302816"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.09.006","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma\u2014Results From a Tertiary Cancer Center in India","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}